OKYO Pharma Limited (OKYO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2025, filed Jul 18, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the OKYO SEC filings page.
This page shows OKYO Pharma Limited (OKYO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers depict a financing-dependent business: losses have narrowed, yet liabilities still exceed assets and short-term coverage remains strained.
In FY2025, operating cash outflow of$1.8M was much smaller than the net loss of$4.7M , so accounting loss did not translate one-for-one into cash use. Compared with the earlier reported period, the corresponding figures were$7.7M and$13.3M , showing the improvement reached cash usage rather than appearing only in earnings.
FY2025 liabilities of
Financing activities supplied net cash of
Financial Health Signals
OKYO Pharma Limited does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
OKYO Pharma Limited reported a net loss of $4.7M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
OKYO Pharma Limited held $1.6M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
OKYO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
OKYO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2510-K | Q4'2410-K | Q4'2310-K | Q4'2210-K | Q4'2110-K |
|---|---|---|---|---|---|
| Total Assets | $3.7M+138.6% | $1.5M-70.4% | $5.2M+21.0% | $4.3M-39.4% | $7.1M |
| Current Assets | $3.7M+139.0% | $1.5M-70.4% | $5.2M+21.0% | $4.3M-38.5% | $7.0M |
| Cash & Equivalents | $1.6M+88.8% | $827K-79.6% | $4.0M+49.8% | $2.7M-60.8% | $6.9M |
| Accounts Receivable | N/A | N/A | $592K-27.2% | $813K+1774.5% | $43K |
| Total Liabilities | $9.2M+24.3% | $7.4M+2.3% | $7.3M+436.3% | $1.4M-23.6% | $1.8M |
| Current Liabilities | $9.2M+24.3% | $7.4M+2.3% | $7.3M+436.3% | $1.4M-20.7% | $1.7M |
| Non-Current Liabilities | $0 | $0 | $0 | $0-100.0% | $65K |
| Long-Term Debt | N/A | N/A | N/A | N/A | $65K |
| Total Equity | -$5.5M+5.6% | -$5.9M-186.4% | -$2.1M-169.7% | $2.9M-44.6% | $5.3M |
| Retained Earnings | -$143.0M-0.4% | -$142.5M-13.4% | -$125.7M-11.8% | -$112.4M-6.1% | -$106.0M |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill.
OKYO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
OKYO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$5.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.40), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| OKYO Pharma Limited OKYO | FY2025 | N/A | -$4.7M | N/A | $75.6M | — |
| Opus Genetics, Inc. IRD | FY2025 | $14.2M | -$49.6M | N/A | $386.0M | 38/100 |
| Sutro Biopharma, Inc. STRO | FY2025 | $102.5M | -$191.0M | N/A | $220.2M | 48/100 |
| Ovid Therapeutics Inc. OVID | FY2025 | $7.3M | -$17.4M | N/A | $470.7M | 66/100 |
| XBiotech Inc XBIT | FY2025 | N/A | -$45.5M | N/A | $69.8M | — |
| Atara Biotherapeutics, Inc ATRA | FY2025 | $120.8M | $32.7M | 27.1% | $94.2M | 63/100 |
Where OKYO Pharma Limited Ranks
Frequently Asked Questions
Is OKYO Pharma Limited profitable?
No, OKYO Pharma Limited (OKYO) reported a net income of -$4.7M in fiscal year 2025.
What is OKYO Pharma Limited's free cash flow?
OKYO Pharma Limited (OKYO) recorded an outflow of $1.8M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is OKYO Pharma Limited's operating cash flow?
OKYO Pharma Limited (OKYO) recorded an outflow of $1.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are OKYO Pharma Limited's total assets?
OKYO Pharma Limited (OKYO) had $3.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are OKYO Pharma Limited's capital expenditures?
OKYO Pharma Limited (OKYO) invested $1K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is OKYO Pharma Limited's current ratio?
OKYO Pharma Limited (OKYO) had a current ratio of 0.40 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is OKYO Pharma Limited's return on assets (ROA)?
OKYO Pharma Limited (OKYO) had a return on assets of -128.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is OKYO Pharma Limited's P/E ratio?
OKYO Pharma Limited (OKYO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $75.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is OKYO Pharma Limited's price-to-sales ratio?
OKYO Pharma Limited (OKYO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $75.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Why is OKYO Pharma Limited's debt-to-equity ratio negative or not reported?
OKYO Pharma Limited (OKYO) has negative shareholder equity of -$5.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Are OKYO Pharma Limited's earnings high quality?
OKYO Pharma Limited (OKYO) reported a net loss of $4.7M while operations used $1.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.